Combination therapy with glucagon and a novel plasminogen activator inhibitor-1-derived peptide enhances protection against impaired cerebrovasodilation during hypotension after traumatic brain injury through inhibition of ERK and JNK MAPK

Glucagon Protects Against Impaired NMDA-Mediated Cerebrovasodilation and Cerebral Autoregulation during Hypotension after Brain Injury by Activating cAMP Protein Kinase A and Inhibiting Upregulation of tPA

(2011) William M. Armstead et al.   JOURNAL OF NEUROTRAUMA

tPA contributes to impaired NMDA cerebrovasodilation after traumatic brain injury through activation of JNK MAPK

(2011) William M Armstead et al.   NEUROLOGICAL RESEARCH

Novel plasminogen activator inhibitor-1-derived peptide protects against impairment of cerebrovasodilation after photothrombosis through inhibition of JNK MAPK

(2010) William M. Armstead et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Neuroprotection by glucagon: role of gluconeogenesis

(2010) Rami Abu Fanne et al.   JOURNAL OF NEUROSURGERY

Blood–brain barrier permeability and tPA-mediated neurotoxicity

(2010) Rami Abu Fanne et al.   NEUROPHARMACOLOGY

Plasminogen activator inhibitor type 1 derived peptide, EEIIMD, diminishes cortical infarct but fails to improve neurological function in aged rats following middle cerebral artery occlusion

(2009) Zhenjun Tan et al.   BRAIN RESEARCH

uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK

(2008) William M. Armstead et al.   BRAIN RESEARCH

uPA Modulates the Age-Dependent Effect of Brain Injury on Cerebral Hemodynamics through LRP and ERK MAPK

(2008) William M Armstead et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Key role of tissue plasminogen activator in neurovascular coupling

(2008) L. Park et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA